Dear stakeholders, As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 11941
Project Team
- Project lead
- Abbie Stephens
Email enquiries
If you have any queries please email Topic.Selection@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 April 2024 | Suspended. Dear stakeholders, As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. |
| 12 December 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 12 December 2023 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual